key: cord-0725012-ivodwccn
authors: Pisano, Thomas John; Hakkinen, Ian; Rybinnik, Igor
title: Large Vessel Occlusion Secondary to COVID-19 Hypercoagulability in a Young Patient: A Case Report and Literature Review
date: 2020-09-10
journal: J Stroke Cerebrovasc Dis
DOI: 10.1016/j.jstrokecerebrovasdis.2020.105307
sha: 7b22ef0e2ccb5886e3c14ef63c5bfd5276dc785c
doc_id: 725012
cord_uid: ivodwccn

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initially most appreciated for its pulmonary symptoms, is now increasingly recognized for causing multi-organ disease and stroke in the setting of a hypercoagulable state. We report a case of 33-year-old African American woman with COVID-19 who developed acute malignant middle cerebral artery infarction due to thromboembolic occlusion of the left terminal internal carotid artery and middle cerebral artery stem. Mechanical thrombectomy was challenging and ultimately unsuccessful resulting in limited reperfusion of <67% of the affected vascular territory, and thrombectomized clot was over 50 mm in length, at least three times the average clot length. The final stroke size was estimated at 224 cubic centimeters. On admission her D-dimer level was 94,589 ng/mL (normal 0–500 ng/ml). Throughout the hospitalization D-dimer decreased but never reached normal values while fibrinogen trended upward. Hypercoagulability panel was remarkable for mildly elevated anticardiolipin IgM of 16.3 MPL/mL (normal: 0–11.0 MPL/mL). With respect to remaining stroke workup, there was no evidence of clinically significant stenosis or dissection in the proximal internal carotid artery or significant cardioembolic source including cardiomyopathy, atrial fibrillation, cardiac thrombus, cardiac tumor, valvular abnormality, aortic arch atheroma, or patent foramen ovale. She developed malignant cytotoxic cerebral edema and succumbed to complications. This case underscores the importance of recognizing hypercoagulability as a cause of severe stroke and poor outcome in young patients with COVID-19 and highlights the need for further studies to define correlation between markers of coagulopathy in patients with COVID-19 infection and outcome post stroke.

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the associated disease is known as the coronavirus disease 2019 (COVID- 19) and was first appreciated for causing severe respiratory symptoms. 1,2 However, reports have emerged describing extrapulmonary involvement and in particular an increased risk for venous and arterial thromboembolism in the form of acute ischemic stroke. 3À5 More alarming are the reports of acute ischemic stroke in patients younger than 50 years of age with SARS-CoV-2 infection, a patient population in which ischemic strokes are relatively infrequent but potentially disabling. 5, 6 In this case report, we describe a young patient with extensive large vessel thrombosis in the setting of PCR confirmed SARS-CoV-2 infection.

Case A 33- year-old African American woman with a past medical history of morbid obesity and no personal or family history of thromboembolic events in first degree relatives, developed cough, fever and fatigue after exposure to a SARS-CoV-2 confirmed family member. The patient initially tried outpatient management with self-quarantine, azithromycin and promethazine dextromethorphan. On day 9 of symptoms, she developed acute right hemiparesis, global aphasia, left gaze deviation and left homonymous hemianopsia and presented to a primary stroke center as a wake-up stroke, 12.5 h after last known well. She arrived outside of the extended 9-h therapeutic window for intravenous thrombolysis and was emergently transferred to a comprehensive stroke center for thrombectomy. The National Institutes of Health Stroke Scale (NIHSS) score was 15 at 12.5 h after last known well. Alberta stroke program early CT score (ASPECTS) was 6 on arrival (Fig. 1) and a left internal carotid artery (ICA) terminus and the proximal middle cerebral artery (M1) occlusion was confirmed with a CT angiogram. CT perfusion was favorable for intervention, and she underwent a challenging mechanical thrombectomy of the terminal ICA and M1 lesions measuring over 50 mm in length utilizing a Trevo 4 £ 30 stent retriever and ACE 68 aspiration catheter. After 3 passes, thrombectomy was ultimately unsuccessful resulting in limited reperfusion of <67% of the affected vascular territory with Thrombolysis in Cerebral Infarction scale (TICI) improving from 0 to 2A. The final stroke size was estimated on a non-contrast head CT at 224 cubic centimeters by the widely accepted Tada Formula of a £ b £ c £ 1/2, where "a" and "b" indicate the perpendicular diameters of the largest area of ischemia, and "c" is the maximal diameter in the remaining third dimension

She was confirmed to be SARS-CoV-2 positive. On admission her D-dimer level was 94,589 ng/mL (normal 0À500 ng/ml). After thrombectomy transiently her D-dimer peaked, while fibrinogen nadired. However, throughout the hospitalization D-dimer decreased but never reached normal values while fibrinogen trended upward (Fig. 2) . Hypercoagulability panel revealed mildly elevated anticardiolipin IgM of 16.3 MPL/mL (normal: 0À11.0 MPL/mL) with the remaining results largely unremarkable (Fig. 2) . With respect to remaining stroke workup, there was no evidence of clinically significant stenosis or dissection in the proximal ICA. Cardioembolic workup only showed a prolonged QTc of 498 ms, likely secondary to her taking azithromycin and a trivially sized pericardial effusion, but showed no evidence of cardiomyopathy, atrial fibrillation, cardiac thrombus, cardiac tumors, valvular abnormalities, aortic arch atheroma, or patent foramen ovale.

Unfortunately, at 38 hours after last known well (25 hours after thrombectomy), she developed signs and symptoms of malignant cerebral edema with uncal and transtentorial herniation which was confirmed radiographically and treated with decompressive hemicraniectomy at 42 hours after last known well (29 hours after thrombectomy). Her hospital course was complicated by sepsis secondary to enterococcus and proteus isolated from blood cultures. The patient had a cardiac arrest on hospital day 11 and subsequently passed despite aggressive resuscitation.

The relative proportion of strokes in the young (under 45 years old) has been increasing over the past few decades. 7 In this age group, African Americans and Hispanics have higher stroke rates than Caucasians. 8 In one study hematologic and vasculopathic etiologies made up 44% of strokes in young patients. 9 In the young, the most common causes are nonatherosclerotic, more often secondary to cardioembolism or arterial dissection, 10 with risk factors including oral contraceptives, smoking, migraine, drug use, infections, vasculitis, connective tissue disease, congenital and acquired thrombophilia, malignancy and pregnancy, amongst others. 7, 10 Depending on the location of occlusion, an average clot length may be 10À16 mm. 11, 12 In the case of our patient, the largest thrombus retrieved was over 50 mm in length (Fig. 2) , at least three times the average clot length. Although there are conflicting data, 13À15 clot length has been associated with decreased reperfusion rate and worse outcome. 16 In fact, the odds ratio for worse outcomes increases by 1.24 for every 5 mm increment over 14 mm. 16 An independent risk factor for stroke (odds ratio 3.4À14.5 17 ) is an inflammation-driven 18 hypercoagulable and vasculopathic state 19 from recent infection, especially respiratory in origin. 20À22 Higher incidence of ischemic stroke has been reported with other respiratory viruses such as influenza. 23, 24 Ischemic stroke has also been observed in other coronaviruses 25 and recent data suggests COVID-19 confers a greater risk of stroke than influenza. 26 Clinical manifestations of COVID-19 often include fatigue, fever, shortness of breath and cough, along with neurological symptoms of anosmia and hypogeusia 27 ; other findings include sore throat, anorexia, myalgia, sputum production, hemoptysis, abdominal pain, nausea and vomiting. 28 SARS-CoV-2 spike glycoprotein gains entry to cells via the angiotensin-converting enzyme 2 (ACE2), which is expressed in oral and nasal mucosa, lung, through the gastrointestinal tract, liver, kidney and the brain. 29 Notably, it is expressed in vascular (arterial and venous) endothelium throughout much of the body. 29 ACE2, part of the brain's renin angiotensin system (RAS), decreases sympathetic tone while increasing both parasympathetic tone and baroreflex sensitivity leading to a net improvement in brain blood pressure regulation. 30 ACE2 activity has been shown to increase atherosclerotic plaque stability, inhibit thrombus formation and is neuroprotective through inhibition of early phase inflammatory response during cerebral ischemic. 31 Cellular infection with SARS-CoV-2 is believed to lead to a decrease of ACE2 expression causing a net vasoconstriction, prothrombotic and proinflammatory state in the brain. 31 Current understanding of COVID-19 suggests an extreme hypercoagulable state, 32,33 that is likely driven by a combination of inflammation 34 and brainwide RAS dysregulation. 31 Linking scientific understanding with paraclinical findings, D-dimer elevation has been shown in stroke patients with recent infection compared with stroke patients without infection. 35 In COVID-19, D-dimer elevation also appears to be an important prognostic marker 2,36 and has been observed in initial COVID-19 stroke patients. 5,6,37 Our patient's dismal outcome correlated with severely elevated D-dimer of about 95,000 ng/ml on admission. Platelet activation, impaired endothelial functioning and dehydration are also thought to play a role in strokes preceded by infection. 38 Concurrent endothelial damage in combination with a hypercoagulable state in COVID-19 disease highly favors thrombus formation. 39 Early reports from China described cerebrovascular disease in about 5% of patients with severe COVID-19 disease, with strokes occurring almost two weeks after initial diagnosis. 37, 40 Chinese populations are estimated to have between 0.1 and 0.7 fold risk for venous thromboembolism (VTE) relative to caucasians. 41À43 As the virus spread across the globe, more recently emergent large vessel occlusion (ELVO) has been reported in non-Chinese patients with COVID-19. 5, 6 As an African American, our patient's ethnicity put her at the greatest risk, 1.2À1.4 fold risk of Caucasians, for VTE. 32, 43, 44 Our patient also had mildly elevated IgM anticardiolipin antibodies, possibly contributing to her hypercoagulable state. 45 In one study, isolated IgM anticardiolipin antibodies made up 14% of patients with antiphospholipid syndrome and having an isolated IgM antiphospholipid syndrome conferred a stroke odds ratio of 3.8. 46 In women, elevated anticardiolipin antibodies are significant for increased risk of stroke. 47 Our patient did not have prior diagnosis of antiphospholipid syndrome, nor did she yet meet criteria for formal diagnosis, which requires two studies separated by a 12 week interval; 48 however, acute infections can lead to short-term increases in anticardiolipin antibodies. 49, 50 Elevated anticardiolipin antibodies have also been observed in patients with thrombotic strokes, 51 including young patients 50 and in patients with infection-associated strokes. 35 Although, it is yet to be determined if elevations are pathogenic or indirect. 22, 50, 52 Elevated IgA anticardiolipin antibodies have been reported in COVID-19 patients with clinically significant coagulopathies. 53 Transient increases in anticardiolipin antibodies could be a mechanism for COVID-19-associated hypercoagulability and may have played a role in this case; however, anticardiolipin antibody levels have not been reported in recent COVID-19 stroke case series. 5, 6 It is imperative that physicians take into consideration the ELVO risk in young patients with COVID-19. Some have suggested prophylactic anticoagulation doses in COVID-19 outpatients, 54 but current NIH guidelines do not support initiating anticoagulation or antiplatelet therapy in VTE prevention of non-hospitalized patients without other risk factors. 55 Patients already on anticoagulation or antiplatelet therapies should be maintained on their current therapy when they are diagnosed with COVID-19. 55 Hospitalized patients with COVID-19 should receive standard VTE-prophylaxis similarly to patients hospitalized without COVID-19. 55 Post-hospitalized COVID-19 patients at VTE risk or presumed to have hospital-associated VTE should receive a full three month course of therapeutic anticoagulation. 56 This case underscores the importance of recognizing hypercoagulability as a cause of severe stroke in young patients with COVID-19, particularly of African American descent, and of assessing and trending markers of coagulopathy, such as D-dimer, fibrinogen and anti-cardiolipin antibodies. Further studies are needed to define specific correlation between markers of coagulopathy in patients with COVID-19 infection and outcome post stroke.

The authors report no disclosures related to this manuscript.

Unfortunately the patient passed. The family gave verbal consent for the patient's case to be published.

T.P. is funded by NINDS F31 NS089303.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in

China: a retrospective cohort study

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

COVID-19 presenting as stroke

Large-vessel stroke as a presenting feature of Covid-19 in the young

Stroke in the young: a global update

Epidemiology of stroke in young adults: race/ethnic differences

Causes of ischemic stroke in young adults, and evolution of the etiological diagnosis over the long term

Aetiological diagnosis of ischaemic stroke in young adults

Mechanical thrombectomy in patients with M1 occlusion and NIHSS score 5: a single-centre experience

Effect of thrombus size on recanalization by bridging intravenous thrombolysis

Impact of thrombus length on recanalization and clinical outcome following mechanical thrombectomy in acute ischemic stroke

Successful recanalization in acute basilar artery occlusion treated with endovascular therapy is independent of thrombus length

Occlusion length is a crucial determinant of efficiency and complication rate in thrombectomy for acute ischemic stroke

Impact of thrombus length on outcomes after intra-arterial aspiration thrombectomy in the therapy trial

Textbook of Stroke Medicine

Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke

Infectious causes of stroke

Common infections and the risk of stroke

Previous infection and stroke: a prospective study

Infection and Risk of Ischemic Stroke

Impact of the fall 2009 influenza A(H1N1)pdm09 pandemic on US hospitals

Influenza-Like Illness as a Trigger for Ischemic Stroke

Large artery ischaemic stroke in severe acute respiratory syndrome (SARS)

Risk of ischemic stroke in patients with Coronavirus Disease 2019 (COVID-19) vs patients with influenza

Coronavirus disease 2019 (COVID-19): a perspective from China

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Angiotensin-converting enzyme 2: a new target for neurogenic hypertension

Coronavirus Disease 2019 and stroke: clinical manifestations and pathophysiological insights

COVID-19 Coagulopathy in Caucasian patients

The Hidden Burden of Influenza: a Review of the Extra-Pulmonary Complications of Influenza Infection. Influenza Other Respi Viruses, 11

The pathogenesis and treatment of the`Cytokine Storm' in COVID-19

Immunohematologic characteristics of infection-associated cerebral infarction

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Neurologic manifestations of hospitalized patients with Coronavirus Disease

Hospitalized infection as a trigger for acute ischemic stroke

Virchow's contribution to the understanding of thrombosis and cellular biology

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

COVID-19 Coagulopathy in Caucasian patients

Effects of race and ethnicity on the incidence of venous thromboembolism

Venous thromboembolism and ethnicity

Effects of race and ethnicity on the incidence of venous thromboembolism

Pathophysiology of the antiphospholipid antibody syndrome

Antiphospholipid syndrome with isolated isotype M anticardiolipin and/or Anti-B2GPI antibody is associated with stroke

Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Anticardiolipin response in acute infections

Anticardiolipin response and its association with infections in young and middle-aged patients with cerebral infarction

Stroke in patients with isolated IgM anticardiolipin antibody

Antiphospholipid antibodies and infections

Coagulopathy and antiphospholipid antibodies in patients with Covid-19

Occurrence of pulmonary embolism in a patient with mild clinical expression of COVID-19

Antithrombotic therapy | Coronavirus Disease COVID-19

COVID-19 Treatment Guidelines

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum